Browsing by Author "Perkin P."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma
    (Taylor and Francis Ltd., 2024) Yildirim H.C.; Bayram E.; Chalabiyev E.; Majidova N.; Avci T.; Güzel H.G.; Kapar C.; Uzun M.; Perkin P.; Akgül F.; Yildirim S.S.; Sali S.; Yildiz A.; Kazaz S.N.; Hendem E.; Arcagok M.; Tufan G.; Yildirim U.; Akgul O.F.; Arslan Ç.; Taban H.; Sahin E.; Caglayan M.; Esen R.; Öksüzoğlu B.; Guven D.C.; Kaplan M.A.; Araz M.; Basaran M.; Cubukcu E.; Gokmen E.; Cicin I.; Algin E.; Semiz H.S.; Tural D.; Ozturk B.; Erdogan A.P.; Sari M.; Kara O.; Erman M.
    Non-clear cell renal cell carcinoma (non-ccRCC) is a highly heterogeneous disease group, accounting for approximately 25% of all RCC cases. Due to its rarity and especially heterogeneity, phase III trial data is limited and treatment options generally follow those of clear cell RCC. In the literature, there exists a number of studies with sunitinib, cabozantinib, and everolimus, but data on the efficacy of pazopanib are limited. Our aim in this study was to compare the efficacy of pazopanib and sunitinib, in a multicenter retrospective cohort of non-ccRCC patients. Our study included patients diagnosed with non-ccRCC who received pazopanib or sunitinib treatment as first-line therapy from 22 tertiary hospitals. We compared the progression-free survival (PFS), overall survival (OS), and response rates of pazopanib and sunitinib treatments. Additionally, we investigated prognostic factors in non-ccRCC. PFS and response rates of sunitinib and pazopanib were found to be similar, while a numerical difference was observed in OS. Being 65 years and older, being in the intermediate or poor risk group according to the International Metastatic Renal Cell Carcinoma Database Consortium, having liver metastases, presence of a sarcomatoid component, and having de novo metastatic disease were found to be significantly associated with shorter PFS. Pazopanib treatment appears to have similar efficacy in the treatment of non-ccRCC compared to sunitinib. Though randomized controlled trials are lacking and will probably be never be available, we suggest that pazopanib could be a preferred agent like sunitinib and cabozantinib. © 2024 Edizioni Scientifiche per l’Informazione su Farmaci e Terapia (Italian Society of Chemotherapy).
  • No Thumbnail Available
    Item
    Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study
    (Taylor and Francis Ltd., 2025) Yildirim H.C.; Kapar C.; Koksal B.; Seyyar M.; Sanci P.C.; Guliyev M.; Perkin P.; Buyukkor M.; Yaslikaya S.; Majidova N.; Keskinkilic M.; Ozaskin D.; Avci T.; Gunes T.K.; Arcagok M.; Topal A.; Keskin G.S.Y.; Kavgaci G.; Yildirim N.; Celayir O.M.; Avci N.; Aslan F.; Alkan A.; Erciyestepe M.; Cengiz M.; Pehlivan M.; Gulmez A.; Beypinar I.; Basoglu Tuylu T.; Kayikcioglu E.; Chalabiyev E.; Turhal S.; Guzel H.G.; Ayas E.; Sahbazlar M.; Dulgar O.; Demir H.; Yavuzsen T.; Bayoglu V.; Kivrak Salim D.; Ozturk B.; Ozdemir F.; Kara O.; Oksuzoglu B.; Bal O.; Demirci N.S.; Yilmaz M.; Cabuk D.; Aksoy S.
    The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is the MONALEESA-7 study, and data on the effectiveness of palbociclib is limited. Data are also limited regarding the effectiveness of CDK 4-6 inhibitors in patients whose dose was reduced due to neutropenia, the most common side effect of CDK 4-6 inhibitors. In our study, we aimed to evaluate the effectiveness of palbociclib and ribociclib in first-line treatment in patients with premenopausal metastatic breast cancer and the effect of dose reduction due to neutropenia on progression-free survival. Our study is a multicenter, retrospective study, and factors affecting progression-free survival (PFS) were examined in patients diagnosed with metastatic premenopausal breast cancer from 29 different centers and receiving combination therapy containing palbociclib or ribociclib in the metastatic stage. 319 patients were included in the study. The mPFS for patients treated with palbociclib was 26.83 months, and for those receiving ribociclib, the mPFS was 29.86 months (p = 0.924). mPFS was 32.00 months in patients who received a reduced dose, and mPFS was 25.96 months in patients who could take the initial dose, and there was no statistical difference (p = 0.238). Liver metastasis, using a fulvestrant together with a CDK 4-6 inhibitor, ECOG PS 1 was found to be a negative prognostic factor. No new adverse events were observed. In our study, we found PFS over 27 months in patients diagnosed with premenopausal breast cancer with CDK 4-6 inhibitors used in first-line treatment, similar to post-menopausal patients. We did not detect any difference between the effectiveness of the two CDK 4-6 inhibitors, and we showed that there was no decrease in the effectiveness of the CDK 4-6 inhibitor in patients whose dose was reduced due to neutropenia. © 2024 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy).